NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03548220,A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD),https://clinicaltrials.gov/study/NCT03548220,,COMPLETED,"Study AG348-C-006 evaluated the efficacy and safety of orally administered AG-348 as compared with placebo in participants with pyruvate kinase (PK) deficiency, who were not regularly receiving blood transfusions. Participants were randomized 1:1 to receive either AG-348 or a matching placebo.",YES,"Pyruvate Kinase Deficiency|Anemia, Hemolytic",DRUG: Placebo|DRUG: AG-348,"Percentage of Participants Achieving a Hemoglobin (Hb) Response (HR), Hemoglobin response (HR) is defined as a â‰¥1.5 g/dL (0.93 mmol/L) increase in Hb concentration from baseline that is sustained at 2 or more scheduled assessments at Weeks 16, 20, and 24. The baseline Hb concentration is the average of all available Hb concentrations for a participant during the Screening Period up to the first dose of study treatment. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo)., Baseline, Weeks 16, 20, 24","Average Change From Baseline in Hb Concentration at Weeks 16, 20 and 24, This is the change in Hb concentration at Weeks 16, 20 and 24 compared to baseline. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo)., Baseline, Weeks 16, 20, 24|Maximum Change From Baseline in Hb Concentration, This is the maximum change from baseline in Hb concentration up to Week 24. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo)., Baseline, up to Week 24|Time to Achieve an Increase in Hb Concentration of 1.5 g/dL or More, This is the time taken to first achieve an increase of hemoglobin concentration of 1.5 g/dL or more from baseline. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo)., Baseline, up to Week 24|Average Change From Baseline in Indirect Bilirubin at Weeks 16, 20 and 24, The change from baseline in indirect bilirubin levels was summarized. Indirect bilirubin is a marker for hemolysis. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo)., Baseline, Weeks 16, 20, 24|Average Change From Baseline in Lactic Acid Dehydrogenase (LDH) at Weeks 16, 20 and 24, The change from baseline in LDH levels was summarized. LDH is a marker for hemolysis. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo)., Baseline, Weeks 16, 20, 24|Average Change From Baseline in Haptoglobin at Weeks 16, 20 and 24, The change from baseline in haptoglobin levels was summarized. Haptoglobin levels are markers for hemolysis. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo)., Baseline, Weeks 16, 20, 24|Average Change From Baseline in Reticulocyte Percentages at Weeks 16, 20 and 24, The change from baseline in reticulocyte percentage was summarized. Reticulocyte levels are markers for hematopoietic activity. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo)., Baseline, Weeks 16, 20, 24|Change From Baseline in Pyruvate Kinase Deficiency Diary (PKDD) Score at Week 24, The PKDD is a 7-item patient reported outcome (PRO) measure of the core signs and symptoms associated with PK deficiency in adults. Participants rate their experience with symptoms of PK deficiency on the present day. The symptoms include those associated with tiredness, jaundice, bone pain, shortness of breath, and energy level. The score ranges from 25 to 76, with higher scores indicating a higher disease burden. The change from baseline in PKDD weekly scores was evaluated. A negative change from baseline indicates a lower disease burden. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo)., Baseline, Week 24|Change From Baseline in Pyruvate Kinase Deficiency Impact Assessment (PKDIA) Score at Week 24, The PKDIA is a 12-item patient reported outcome (PRO) measure of the common impacts of PK deficiency on activities of daily living. Participants rate how PK deficiency has impacted aspects of daily living in the past 7 days, including impacts on relationships; perceived appearance; work performance; and leisure, social, mental, and physical activities. The score range is 30 to 76, with higher scores indicating a higher disease burden. The change from baseline in PKDIA scores was evaluated. A negative change from baseline indicates a lower disease burden. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo)., Baseline, Week 24|Percentage of Participants With Adverse Events, An AE is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product., From signing of informed consent form to the end of study, including follow-up (up to Day 197)|Area Under the Curve From Time 0 to the Last Quantifiable Concentration [AUC(0-last)] for AG-348 at Week 12, Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12)|Maximum Plasma Concentration (Cmax) for AG-348, Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12)|Time to Cmax (Tmax) for AG-348, Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12)|Time to Last Measurable Concentration (Tlast) for AG-348, Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12)|Exposure-Response Relationship of Adverse Event (Hot Flush) and AG-348 Concentration and Relevant AG-348 Pharmacokinetic Parameters, Predicted probability of experiencing all grade hot flush at the doses of 5, 20, and 50 mg mitapivat BID based on exposure-response model., From first dose of mitapivat to the end of study, including follow-up (up to Day 197)|Exposure-Response Relationship Between Safety Parameters (Sex Hormone in Male Subjects) and AG-348 Concentration and Relevant AG-348 Pharmacokinetic Parameters, Predicted percent change from baseline at Week 24 in the sex hormone measures (total testosterone, free testosterone, and estrone) at the doses of 5, 20, and 50 mg mitapivat BID in male participants., Baseline, Week 24","Percentage of Participants With Adverse Events of Special Interest (AESI), An AE is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AESI can be serious or non-serious., Through 4 weeks after last dose (approximately Week 31)|Change From Baseline in Bone Mineral Density Z-Score at Week 24, Baseline, Week 24|Change From Baseline in Bone Mineral Density T-Score at Week 24, Baseline, Week 24","Agios Pharmaceuticals, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,80,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",AG348-C-006,2018-08-09,2020-10-09,2020-10-09,2018-06-07,2022-05-24,2022-05-24,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States|Emory University, Atlanta, Georgia, 30322, United States|Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, 46260, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|The Children's Hospital Corporation d/b/a Boston's Children Hospital, Boston, Massachusetts, 02115, United States|Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, Michigan, 48304, United States|Duke University, Durham, North Carolina, 27705, United States|East Carolina University, Greenville, North Carolina, 27858, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|Houston Methodist Research Institute, Houston, Texas, 77030, United States|Primary Children's Hospital Univ. of Utah, Salt Lake City, Utah, 84112, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Hospital Central da Faculdade de Medicina USP Cidade Universitaria, SÃ£o Paulo, Brazil|McMaster University - Health Sciences Centre, Hamilton, L8S 4LB, Canada|Toronto General Hospital, University Health Network, Toronto, M5G 2C4, Canada|Institute of Hematology and Blood Transfusion, Prague, Czechia|University of Copenhagen, Herlev Hospital, Herlev, 2730, Denmark|CHU Amiens Picardie, Amiens, 80054, France|Hopital Saint-Andre, Bordeaux, France|HÃ´pital Henri-Mondor, CrÃ©teil, 94010, France|HÃ´pital de la Timone, Marseille, Cedex 5, 13385, France|Institut Claudius Regaud, Toulouse, France|Charite University Medicine, Berlin, Germany|UniversitÃ¤tsklinikum WÃ¼rzburg, WÃ¼rzburg, 97080, Germany|Ospedale Galliera, Genova, 16128, Italy|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, 20122, Italy|AOU Policlinico, UniversitÃ  della Campania ""Luigi Vanvitelli"", Napoli, 80138, Italy|Tohoku University Hospital, Sendai-City, Miyagi, Japan|Kyoto Katsura Hospital, Kyoto, Japan|Agios Investigative Site, Mie, Japan|Osaka City General Hospital, Osaka, 534-0021, Japan|Kansai Medical University, Department of Pediatrics, Hirakata Hospital, Osaka, Japan|Toho University Omori Medical Center, Tokyo, Japan|Yeungnam University Hospital, Daegu 705-703, 42415, Korea, Republic of|Universitair Medisch Centrum Utrecht, Utrecht, 3584, Netherlands|Hospital U. Vall d'Hebron Servicio de HematologÃ­a ClÃ­nica, Barcelona, 08035, Spain|Hospital Clinico Universitario Virgen de la Arricaxa, El Palmar, 30120, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, 1011, Switzerland|Department of Paediatrics and Thalassaemia Center, Faculty of Medicine Siriraj, Bangkok, 10700, Thailand|Hacettepe University, Ankara, Turkey|Addenbrooke's Hospital, Cambridge, 94609, United Kingdom|The Royal Liverpool and Broadgreen University, Liverpool, L7 8XP, United Kingdom|Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, W12 0NN, United Kingdom|University College London, London, W12 0NN, United Kingdom|Manchester Royal Infirmary, Manchester, M13 9WL, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/20/NCT03548220/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/20/NCT03548220/SAP_002.pdf"
